Chemo, immunotherapy, and radiation for stomach cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenocarcinoma of the gastroesophageal junction (where the stomach meets the esophagus).
- You have not received any chemotherapy or radiation for this cancer before.
- Your cancer is locally advanced but has not spread to other organs (stages T2-4, any N, M0).
- You are 18 or older and in good general health (ECOG 0 or 1).
- Your blood counts and kidney/liver function are within normal limits (specific lab thresholds apply).
- You are not pregnant and agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This trial tests whether adding a targeted radiation treatment during surgery to the usual combination of immunotherapy and chemotherapy helps people with advanced stomach cancer before they have surgery to remove the tumor. The goal is to see if this extra treatment can improve outcomes.
Hear when a new Gastroesophageal Junction (GEJ) Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.